Evidence continues to mount that venture capitalists have tightened their purse strings drastically this year. Set against the backdrop of a flat-lined IPO market is the discovery that VC-related investments into biotechnology have dropped off sharply so far this year. Despite the fact the sector was the break-out story of 2000, it appears even its success has succumbed to the current market atmosphere.
According to our